


**Product Name** : FF-10101  
**Cat. No.** : PC-38618  
**CAS No.** : 1472797-69-5  
**Molecular Formula** : C<sub>29</sub>H<sub>38</sub>N<sub>8</sub>O<sub>2</sub>  
**Molecular Weight** : 530.677  
**Target** : FLT3  
**Solubility** : 10 mM in DMSO



## Biological Activity

FF-10101 (FF10101) is a potent, selective, and irreversible FLT3 inhibitor with IC<sub>50</sub> of 0.14 nM (FLT3 Wt), covalent binds to the C695 residue of FLT3.

FF-10101 potently inhibited the phosphorylation of FLT3-ITD than that of FLT3-ITD-C695S (IC<sub>50</sub> values 2.4 nM and 79 nM, respectively).

FF-10101 potently and selectively inhibits the growth of mutant FLT3-expressing leukemia cells in vitro (MV4-11 c ell, IC<sub>50</sub>=0.83 nM), potently inhibits kinase activities of wild-type FLT3 and FLT3-D835Y with IC<sub>50</sub> values of 0.20 nM and 0.16 nM, respectively.

FF-10101 demonstrated high kinase selectivity to wild-type FLT3 with >30-fold margins against the other kinases except for FMS and KIT with IC<sub>50</sub> values of 0.94 nM and 2.0 nM, respectively.

FF-10101 showed growth inhibitory effects on all tested types of FLT3-TKD mutation- and FLT3-ITD with D835Y, Y842C, Y842H, or F691L mutation-expressing 32D cells with GI<sub>50</sub> values from 0.43 nM to 6.1 nM.

FF-10101 (2, 5, and 10 mg/kg) demonstrated anti-leukemic effects in in vivo models, FF-10101 more potently inhibited the growth of tumors with FLT3-ITD-D835Y and FLT3-ITD-F691L than quizartinib.

## References

Yamaura T, et al. Blood. 2018 Jan 25;131(4):426-438.

Feng TT, et al. Mol Cancer Ther. 2022 Apr 8:OF1-OF11.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com